Kestra Raises FY26 Revenue Guidance to $93 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy KMTS?
The company said, "Kestra is increasing its FY26 revenue guidance to $93 million, which would represent growth of 55% compared to FY25. This compares to prior FY26 revenue guidance of $91 million and initial FY26 guidance of $85 million."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KMTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KMTS
Wall Street analysts forecast KMTS stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.330
Low
27.00
Averages
29.50
High
32.00
Current: 18.330
Low
27.00
Averages
29.50
High
32.00
About KMTS
Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sprott Focus Trust and Kestra Medical Insider Purchases
- Insider Trading Activity: W. Whitney George of Sprott Focus Trust made a significant purchase of 135,086 shares of FUND at $8.96 each on Friday, totaling $1.21 million, indicating strong confidence in the stock.
- Return on Investment: At the peak of trading, George's investment saw an 8.2% return, with FUND reaching a high of $9.69 on Tuesday, reflecting positive market sentiment towards the stock.
- Historical Purchase Record: Prior to this transaction, George had purchased FUND four times over the past year, spending a total of $5.26 million at an average cost of $8.12 per share, demonstrating his sustained bullish outlook on the stock.
- Kestra Medical Purchase Details: Concurrently, Raymond W. Cohen bought 10,000 shares of Kestra Medical Technologies at $19.98 each on Thursday, amounting to $199,800, showcasing confidence in the company's prospects.
See More
Kestra Medical Technologies Reports Strong Q3 Earnings Growth
- Significant Revenue Growth: Kestra Medical Technologies reported Q3 revenue of $24.6 million, a 63% year-over-year increase, indicating the company's growing competitiveness in the market and potential to attract further investor interest.
- Gross Margin Improvement: The company achieved a gross margin of 52.6%, up 9 percentage points from the prior year, marking nine consecutive quarters of margin expansion, which highlights the attractiveness of its business model and improved profitability.
- Increase in Prescriptions: The number of prescriptions for the Essure system reached 5,400, a 58% year-over-year increase, reflecting not only rising market demand but also the company's successful expansion in market share.
- Rising Operating Expenses: Despite revenue growth, GAAP operating expenses rose to $47.7 million, a nearly 76% increase from the prior year, primarily driven by investments in commercial expansion and public company costs, which may pressure short-term profitability.
See More
Kestra Medical Technologies Reports Strong Q3 2026 Earnings Growth
- Strong Financial Performance: Kestra Medical Technologies reported $24.6 million in revenue for Q3 2026, reflecting a 63% year-over-year growth, with a gross margin of 52.6%, up 9 percentage points from the previous year, indicating robust demand and attractive unit economics of its business model.
- FDA Approval of New Algorithm: The company received FDA approval for an updated ASSURE algorithm, expected to significantly reduce false alarms and inappropriate shocks, which are critical for enhancing patient experience and clinical performance, thereby solidifying its market position.
- Strategic Collaboration Expansion: Kestra entered into a strategic collaboration with Biobeat Technologies, investing $5 million to integrate its blood pressure monitoring technology, aimed at enhancing diagnostic capabilities for the ASSURE WCD and increasing product competitiveness in the market.
- Market Access Progress: The company became an approved provider for Florida's managed Medicaid plans and signed contracts with two of the four largest plans in the state, further expanding its market reach and expected to drive future revenue growth.
See More
Kestra Medical Technologies Q3 Earnings Exceed Expectations
- Strong Earnings Performance: Kestra Medical Technologies reported a Q3 GAAP EPS of $0.61, beating market expectations by $1.21, which indicates a significant improvement in profitability and boosts investor confidence.
- Robust Revenue Growth: The company achieved Q3 revenue of $24.55 million, reflecting a year-over-year increase of 62.7% and exceeding expectations by $1.68 million, showcasing strong product demand and market share expansion.
- Increased Market Recognition: Kestra Medical Technologies presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the medical technology sector, which could attract potential investors and partners.
- Historical Performance Data Support: The historical financial data provided by the company indicates a consistent trend of revenue and profit growth, establishing a solid foundation for future business expansion and strengthening its position in the competitive medical technology market.
See More
Kestra Medical Technologies Partners with Biobeat for $5 Million Investment to Enhance Cardiac Recovery Monitoring
- Strategic Collaboration: Kestra Medical Technologies has entered into a strategic collaboration with Biobeat Technologies, involving a $5 million equity investment aimed at integrating Biobeat's cuffless blood pressure monitoring technology into the ASSURE® Wearable Cardioverter Defibrillator, thereby enhancing patient monitoring capabilities and clinical decision support.
- Technological Integration Benefits: Biobeat's FDA-cleared cuffless blood pressure monitoring device provides continuous 24-hour blood pressure data, which will enable Kestra to offer more comprehensive health monitoring for patients during cardiac recovery, particularly in managing hypertensive patients.
- Clinical Research Support: The recent clinical evaluation study of the ASSURE wearable cardioverter defibrillator by Kestra revealed that 72% of participants were hypertensive, underscoring the importance of blood pressure monitoring during cardiac recovery and providing stronger evidence for clinical decision-making.
- Market Outlook: This collaboration not only enhances Kestra's competitiveness in cardiac health monitoring but also demonstrates its strategic vision in promoting at-home patient care and optimizing medical decision-making, which is expected to attract more attention from healthcare providers.
See More
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra Medical Technologies' investor relations website, which will help enhance the company's visibility and transparency among investors.
- Company Background: Kestra Medical Technologies focuses on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, demonstrating its innovative potential in the digital healthcare sector.
- Market Positioning: As a commercial-stage wearable medical device company, Kestra's technology aims to improve patient health outcomes, indicating its strategic significance in the rapidly evolving digital healthcare market.
See More
Sprott Focus Trust and Kestra Medical Insider Purchases
- Insider Trading Activity: W. Whitney George of Sprott Focus Trust made a significant purchase of 135,086 shares of FUND at $8.96 each on Friday, totaling $1.21 million, indicating strong confidence in the stock.
- Return on Investment: At the peak of trading, George's investment saw an 8.2% return, with FUND reaching a high of $9.69 on Tuesday, reflecting positive market sentiment towards the stock.
- Historical Purchase Record: Prior to this transaction, George had purchased FUND four times over the past year, spending a total of $5.26 million at an average cost of $8.12 per share, demonstrating his sustained bullish outlook on the stock.
- Kestra Medical Purchase Details: Concurrently, Raymond W. Cohen bought 10,000 shares of Kestra Medical Technologies at $19.98 each on Thursday, amounting to $199,800, showcasing confidence in the company's prospects.
See More
Kestra Medical Technologies Reports Strong Q3 Earnings Growth
- Significant Revenue Growth: Kestra Medical Technologies reported Q3 revenue of $24.6 million, a 63% year-over-year increase, indicating the company's growing competitiveness in the market and potential to attract further investor interest.
- Gross Margin Improvement: The company achieved a gross margin of 52.6%, up 9 percentage points from the prior year, marking nine consecutive quarters of margin expansion, which highlights the attractiveness of its business model and improved profitability.
- Increase in Prescriptions: The number of prescriptions for the Essure system reached 5,400, a 58% year-over-year increase, reflecting not only rising market demand but also the company's successful expansion in market share.
- Rising Operating Expenses: Despite revenue growth, GAAP operating expenses rose to $47.7 million, a nearly 76% increase from the prior year, primarily driven by investments in commercial expansion and public company costs, which may pressure short-term profitability.
See More
Kestra Medical Technologies Reports Strong Q3 2026 Earnings Growth
- Strong Financial Performance: Kestra Medical Technologies reported $24.6 million in revenue for Q3 2026, reflecting a 63% year-over-year growth, with a gross margin of 52.6%, up 9 percentage points from the previous year, indicating robust demand and attractive unit economics of its business model.
- FDA Approval of New Algorithm: The company received FDA approval for an updated ASSURE algorithm, expected to significantly reduce false alarms and inappropriate shocks, which are critical for enhancing patient experience and clinical performance, thereby solidifying its market position.
- Strategic Collaboration Expansion: Kestra entered into a strategic collaboration with Biobeat Technologies, investing $5 million to integrate its blood pressure monitoring technology, aimed at enhancing diagnostic capabilities for the ASSURE WCD and increasing product competitiveness in the market.
- Market Access Progress: The company became an approved provider for Florida's managed Medicaid plans and signed contracts with two of the four largest plans in the state, further expanding its market reach and expected to drive future revenue growth.
See More
Kestra Medical Technologies Q3 Earnings Exceed Expectations
- Strong Earnings Performance: Kestra Medical Technologies reported a Q3 GAAP EPS of $0.61, beating market expectations by $1.21, which indicates a significant improvement in profitability and boosts investor confidence.
- Robust Revenue Growth: The company achieved Q3 revenue of $24.55 million, reflecting a year-over-year increase of 62.7% and exceeding expectations by $1.68 million, showcasing strong product demand and market share expansion.
- Increased Market Recognition: Kestra Medical Technologies presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the medical technology sector, which could attract potential investors and partners.
- Historical Performance Data Support: The historical financial data provided by the company indicates a consistent trend of revenue and profit growth, establishing a solid foundation for future business expansion and strengthening its position in the competitive medical technology market.
See More
Kestra Medical Technologies Partners with Biobeat for $5 Million Investment to Enhance Cardiac Recovery Monitoring
- Strategic Collaboration: Kestra Medical Technologies has entered into a strategic collaboration with Biobeat Technologies, involving a $5 million equity investment aimed at integrating Biobeat's cuffless blood pressure monitoring technology into the ASSURE® Wearable Cardioverter Defibrillator, thereby enhancing patient monitoring capabilities and clinical decision support.
- Technological Integration Benefits: Biobeat's FDA-cleared cuffless blood pressure monitoring device provides continuous 24-hour blood pressure data, which will enable Kestra to offer more comprehensive health monitoring for patients during cardiac recovery, particularly in managing hypertensive patients.
- Clinical Research Support: The recent clinical evaluation study of the ASSURE wearable cardioverter defibrillator by Kestra revealed that 72% of participants were hypertensive, underscoring the importance of blood pressure monitoring during cardiac recovery and providing stronger evidence for clinical decision-making.
- Market Outlook: This collaboration not only enhances Kestra's competitiveness in cardiac health monitoring but also demonstrates its strategic vision in promoting at-home patient care and optimizing medical decision-making, which is expected to attract more attention from healthcare providers.
See More
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra Medical Technologies' investor relations website, which will help enhance the company's visibility and transparency among investors.
- Company Background: Kestra Medical Technologies focuses on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, demonstrating its innovative potential in the digital healthcare sector.
- Market Positioning: As a commercial-stage wearable medical device company, Kestra's technology aims to improve patient health outcomes, indicating its strategic significance in the rapidly evolving digital healthcare market.
See More
